COVID-19 Adaptive Humoral Immunity Models: Weakly Neutralizing Versus Antibody-Disease Enhancement Scenarios
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2020.10.21.20216713: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:As any other, our model contains of course several limitations. First, we considered all infected cells to support viral replication, including ADE-infected cells. Concerning SARS-CoV-2, the questions of ADE is still under debate, but for SARS-CoV-1 in vitro ADE evidence suggested abortive viral replication in ADE infected cells. …
SciScore for 10.1101/2020.10.21.20216713: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:As any other, our model contains of course several limitations. First, we considered all infected cells to support viral replication, including ADE-infected cells. Concerning SARS-CoV-2, the questions of ADE is still under debate, but for SARS-CoV-1 in vitro ADE evidence suggested abortive viral replication in ADE infected cells. Therefore, if we changed the model (1)-(4) to include this distinction, equilibrium state would change and ADE may be compensated. Similarly, we did not distinguish between former antibodies and novel antibodies secreted upon challenge. This would imply more parameters and change equilibrium levels but without inherently changing variables behaviour. Regarding parameters, we did not have enough exploitable available data to train our model and fit parameters better. Finally, an unique model can hardly capture the extreme variability of COVID-19 clinical outcomes, see [38]; some studies proposed that some of the variability come from genetics, see e.g., [39] where genetic information from roughly 4,000 people from Italy and Spain was correlated to severity of COVID-19. This may lead to a variability of our model parameters in the form of random variables. The more science will shed light on the full picture of SARS-CoV-2, the more our model can input complex and precise details. In the meantime, the main take-home message is that, with parameters consistent with the available clinical data, the neutralizing capacity and ADE mechanisms may play an impo...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-